Search research articles
Contact Us
Filters
Showing results (111-120 of 271) with videos related to
Page
of 28
Sort By:
European Urology Focus
|
April 27, 2025
STARLITE 1: Phase 1b/2 Study of Combined <sup>177</sup>Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma
Elshad Hasanov, Lesley Flynt, Rebecca Slack Tidwell, et al.
Current Medical Research and Opinion
|
January 9, 2016
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review
Nicholas J Vogelzang, Sumanta K Pal, James E Signorovitch, et al.
European Urology
|
May 31, 2011
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma
Brian F Chapin, Scott E Delacroix, Stephen H Culp, et al.
Journal of Biomolecular Screening
|
February 24, 2012
Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis
Zhiyong Ding, Peter German, Shanshan Bai, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
August 3, 2015
The PI3K/AKT Pathway and Renal Cell Carcinoma
Huifang Guo, Peter German, Shanshan Bai, et al.
The Journal of Urology
|
July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Nizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2013
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas
Qi Zhao, Otavia L Caballero, Ian D Davis, et al.
BJU International
|
April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma
Danai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
BMC Genomics
|
October 7, 2017
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening
Guangchun Han, Wei Zhao, Xiaofeng Song, et al.
European Urology
|
February 20, 2013
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study
Patricia A Parker, Frances Alba, Bryan Fellman, et al.
Page
of 28
Search research articles
Search
Showing results (111-120 of 271) with videos related to
Sort By:
Page
of 28
European Urology Focus
|
April 27, 2025
STARLITE 1: Phase 1b/2 Study of Combined <sup>177</sup>Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma
Elshad Hasanov, Lesley Flynt, Rebecca Slack Tidwell, et al.
Current Medical Research and Opinion
|
January 9, 2016
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review
Nicholas J Vogelzang, Sumanta K Pal, James E Signorovitch, et al.
European Urology
|
May 31, 2011
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma
Brian F Chapin, Scott E Delacroix, Stephen H Culp, et al.
Journal of Biomolecular Screening
|
February 24, 2012
Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis
Zhiyong Ding, Peter German, Shanshan Bai, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
August 3, 2015
The PI3K/AKT Pathway and Renal Cell Carcinoma
Huifang Guo, Peter German, Shanshan Bai, et al.
The Journal of Urology
|
July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Nizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2013
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas
Qi Zhao, Otavia L Caballero, Ian D Davis, et al.
BJU International
|
April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma
Danai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
BMC Genomics
|
October 7, 2017
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening
Guangchun Han, Wei Zhao, Xiaofeng Song, et al.
European Urology
|
February 20, 2013
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study
Patricia A Parker, Frances Alba, Bryan Fellman, et al.
Page
of 28